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Abstract
Background Atopic eczema or dermatitis (AD) is asso-
ciated with atopy and is characterized by reduced skin
hydration and an impaired skin barrier in the epidermis.
We investigated the patient acceptability and efficacy of an
emollient containing ceramide-precursor lipids and mois-
turizing factors (LMF) in AD.
Methods Consecutive AD patients were recruited. Swabs
and cultures were obtained from the right antecubital fossa
and the worst-affected eczematous area, and disease
severity [according to the SCORing Atopic Dermatitis
(SCORAD) Index], skin hydration, and transepidermal
water loss (TEWL) were measured prior to and after 2
weeks’ use of the LMF moisturizer. The general accept-
ability of treatment was documented as being ‘very good’,
‘good’, ‘fair’, or ‘poor’.
Results Twenty-four AD patients [mean age 13.8 (stan-
dard deviation 5.7) years] were recruited. Two thirds of the
patients reported very good or good acceptability of the
LMF moisturizer, whereas one third reported fair or poor
acceptability. There were no inter-group differences in the
pre-use clinical parameters of age, objective SCORAD
score, pruritus score, sleep disturbance score, skin
hydration, TEWL, topical corticosteroid use, oral antihis-
tamine use, or acceptability of previously used proprietary
emollients. However, patients in the fair/poor acceptability
group were more likely to have Staphylococcus aureus
colonization and to be female (odds ratio 13, 95 % confi-
dence interval 1.7–99.4; p = 0.021). Following use of the
LMF moisturizer, the objective SCORAD score, pruritus
score, and sleep disturbance score were lower in the very
good/good acceptability group than in the fair/poor
acceptability group. The mean objective SCORAD score
improved (from 31.5 to 25.7; p = 0.039) and skin hydra-
tion improved [from 30.7 arbitrary units (a.u.) to 36.0 a.u.;
p = 0.021] in the very good/good acceptability group.
When the data were analyzed for the strength of the
agreement of the rating of acceptability, the j values were
0.338 (fair) for use of body wash and 0.118 (poor) for use
of emollients before and after the trial.
Conclusion The LMF moisturizer was considered
acceptable by two thirds of the patients with AD. It seems
that patients who found the moisturizer acceptable were
less likely to be female or to be colonized by S. aureus
before switching to the product, and they had less severe
eczema, less pruritus, and less sleep disturbance after its
use than patients who did not find the product acceptable.
Gender and S. aureus colonization may have influenced the
patient acceptability and clinical efficacy of the LMF
moisturizer. The lack of agreement with regard to the
acceptability of the moisturizer implies that there is room
for parent/patient education to improve compliance.
1 Introduction
Atopic eczema or dermatitis (AD) is a chronically relaps-
ing dermatosis associated with atopy and is characterized
K. L. Hon (&)  N. H. Pong  S. S. Wang  T. F. Leung
Department of Paediatrics, Prince of Wales Hospital,
The Chinese University of Hong Kong, 6/F,
Clinical Science Building, Shatin, Hong Kong
e-mail: ehon@hotmail.com
V. W. Lee
School of Pharmacy, The Chinese University of Hong Kong,
Shatin, Hong Kong
N. M. Luk
Dermatology Research Centre, The Chinese University of Hong
Kong, Shatin, Hong Kong
Drugs R D (2013) 13:37–42
DOI 10.1007/s40268-013-0004-x
by reduced skin hydration, impaired skin integrity [trans-
epidermal water loss (TEWL)], and poor quality of life as a
result of deficient ceramides in the epidermis [1]. Regular
application of a moisturizer is the key to management of
AD. Moisturizer therapy for AD is significantly compli-
cated by the diversity of disease manifestations and by a
variety of complex immune abnormalities [1]. Filaggrin
(filament-aggregating protein) has an important function in
epidermal differentiation and barrier function, and null
mutations within the filaggrin (FLG) gene are major risk
factors for developing AD [2–6]. Recent advances in the
understanding of the pathophysiological process of AD
have led to the production of new moisturizers and topical
skin products containing ceramides, pseudoceramides, or
natural moisturizing factors targeted at correcting the
reduced amount of ceramides and natural moisturizing
factors in the stratum corneum [7]. However, many pro-
prietary products that claim to contain these ingredients
have no or only limited studies to document their clinical
efficacy. Furthermore, independently of the ingredients,
patient preference and acceptability may influence the
outcomes of topical treatment [8]. The purposes of this
study were to investigate the patient acceptability of a
product containing ceramide-precursor lipids and moistur-
izing factors (LMF), and to evaluate its efficacy in
improving the clinical and biophysiological properties of
the skin of AD patients.
2 Methods
Patients with AD were recruited from the pediatric der-
matology clinic at a teaching hospital. AD was diagnosed
according to the UK Working Party’s criteria [9]. Skin
hydration, TEWL on the right forearm (2 cm below the
antecubital flexure), and disease severity [according to the
SCORing Atopic Dermatitis (SCORAD) Index] were
measured. We have previously described our method of
standardizing measurements of skin hydration and TEWL
[10]. After acclimatization in the consulting room with the
patient sitting comfortably in a chair for 20 to 30 minutes,
skin hydration [in arbitrary units (a.u.)] and TEWL (in
g/m2/h) were measured with a Mobile Skin Center MSC
100 equipped with a Corneometer CM 825 and a Tew-
ameter TM 210 probe (Courage & Khazaka Electronic
GmbH, Cologne, Germany), according to the manufac-
turer’s instructions. We documented that a site 2 cm distal
to the right antecubital flexure was optimal for standardi-
zation. Oozing and infected areas were avoided by moving
the probe slightly sideways [10]. The clinical severity of
AD was assessed with the SCORAD Index [11, 12].
Patients were given a liberal supply of the LMF mois-
turizer (Cetaphil RESTORADERMTM Lotion; Galderma
Canada Inc., Thornhill, ON, Canada) and moisturizing
wash (Cetaphil RESTORADERMTM Wash; Galderma
Canada Inc.). The moisturizer claims to contain purified
water, glycerin, caprylic/capric triglyceride, Helianthus
annuus (sunflower) seed oil, pentylene glycol, Butyro-
spermum parkii (shea butter), sorbitol, cyclopentasiloxane,
cetearyl alcohol, behenyl alcohol, glyceryl stearate, toc-
opheryl acetate, hydroxypalmitoyl sphinganine (0.01 %
w/w), cetyl alcohol, arginine (0.50 % w/w), disodium
ethylene dicocamide polyethylene glycol (PEG)-15 disul-
fate, glyceryl stearate citrate, niacinamide, sodium pyrrol-
idone carboxylate (PCA) [0.50 % w/w], ceteareth-20,
sodium polyacrylate, caprylyl glycol, allantoin, citric acid,
panthenol, dimethiconol, disodium ethylenediaminete-
traacetic acid (EDTA), and sodium hyaluronate. Hydroxy-
palmitoyl sphinganine is a ceramide precursor. Arginine
and sodium PCA are natural moisturizing factors. Arginine
acts as a substrate not only for arginase but also for nitric
oxide synthase.
The moisturizing wash contains purified water, B. parkii,
sodium trideceth sulfate, glycerin, H. annuus seed oil, sodium
chloride, sodium lauramphoacetate, cocamide monoethanol-
amine (MEA), citric acid, niacinamide, sodium PCA (0.50 %
w/w), tocopheryl acetate, 1,2-hexanediol and caprylyl glycol,
disodium EDTA, guar hydroxypropyltrimonium chloride,
allantoin, potassium sorbate, arginine (0.10 % w/w), and
methylisothiazolinone.
The patients were instructed not to use any other topical
treatment except for their usual corticosteroid on an as-
necessary basis. They were encouraged to use the LMF
moisturizer at least twice daily on the flexures and areas
with eczema. In the event that the emollient effect was not
satisfactory, they could use their usual emollient and
medications, but the frequency of such use was to be
reported, and they must continue using the LMF moistur-
izer. The patients were reviewed at the end of 2 weeks.
Measurements of the SCORAD score, Children’s Derma-
tology Life Quality Index (CDLQI), skin hydration, and
TEWL were repeated. The patient’s global or general
acceptability of treatment (GAT) was recorded as ‘very
good’, ‘good’, ‘fair’, or ‘poor’ [8, 13]. Ethical approval for
the study was obtained from the Clinical Research Ethics
Committee of the Chinese University of Hong Kong, and
written informed consent was obtained from each patient
and his/her guardian.
Continuous data are expressed as means and standard
deviations (SDs). The Mann-Whitney U test for inter-group
comparisons and the McNemar test for within-group
comparisons with small numbers of subjects were used.
Categorical data are presented as counts. The v2 test or
Fisher’s exact test, where appropriate, were used to com-
pare categorical data. j values were determined for the
previously used proprietary products and for the LMF
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moisturizer and moisturizing wash. All comparisons were
two-tailed, and p values of B0.05 were considered statis-
tically significant.
3 Results
Between December 2011 and June 2012, 24 patients [63 %
male; mean age 13.8 (SD 5.7) years] with AD were
recruited and treated with applications of the LMF mois-
turizer and moisturizing wash. Compliance was good, and
patients generally managed to use the moisturizer daily.
Two thirds reported very good or good acceptability of the
LMF moisturizer, whereas one third reported fair or poor
acceptability (Tables 1, 2; the male percentages were 81 %
and 25 %, respectively; p = 0.021).
There were no inter-group differences in pre-use clinical
parameters of age, the objective SCORAD score, pruritus
score, sleep disturbance score, skin hydration, TEWL,
topical corticosteroid use, oral antihistamine use, or
acceptability of the previously used proprietary emollients.
However, patients in the fair/poor acceptability group were
more likely to have Staphylococcus aureus colonization
and to be female (odds ratio 13, 95 % confidence interval
1.7–99.4; p = 0.021). Following use of the LMF moistur-
izer, the objective SCORAD score, pruritus score, and
sleep disturbance scores were lower in the very good/good
acceptability group than in the fair/poor acceptability
group. The mean objective SCORAD score improved
(from 31.5 g/m2/h to 25.7 g/m2/h; p = 0.039) and skin
hydration improved (from 30.7 a.u. to 36.0 a.u.; p = 0.021)
in the very good/good acceptability group.
When the data were analyzed for the strength of the
agreement of the rating of acceptability, the j values were
0.338 (fair) for use of body wash and 0.118 (poor) for use
of emollients before and after the trial. Neither result
reached statistical significance, implying that there
appeared to be no consistency in agreement (or preference).
Patients who preferred the LMF moisturizer or moisturiz-
ing wash may or may not have come from the group of
poor/fair acceptability of their previous emollient or body
wash. Previously used products included emulsifying
ointment, QVTM, Johnson and Johnson, Sebamed, and
various other proprietary products.
4 Discussion
AD is a chronically relapsing dermatosis characterized by
pruritus, erythema, vesiculation, papulation, exudation,
excoriation, crusting, scaling, and sometimes lichenification
[1, 14]. Secondary bacterial infection, most commonly with
S. aureus, is the main complication [1, 15, 16]. In the brick-
and-mortar hypothesis, the stratum corneum (the outermost
layer of the epidermis) normally consists of fully differen-
tiated corneocytes surrounded by a lipid-rich matrix con-
taining cholesterol, free fatty acids, and ceramides. In AD,
lipid metabolism is abnormal, causing a deficiency of
ceramides and natural moisturizing factors, and impairment
of epidermal barrier function, which leads to increased
TEWL [1, 7, 17, 18]. It has been shown that loss-of-function
mutations in the FLG gene predispose to AD [2–6, 19, 20].
The protein is present in the granular layers of the epider-
mis. The keratohyalin granules in the granular layers are
predominantly composed of profilaggrin [21]. Filaggrin
aggregates the keratin cytoskeleton system to form a dense
protein-lipid matrix, which is cross-linked by transgluta-
minases to form a cornified cell envelope [4, 21]. The latter
prevents epidermal water loss and impedes the entry of
allergens, infectious agents, and chemicals [4, 22].
The key to management of AD and dry skin conditions,
especially in between episodes of flare ups, is frequent use
of an appropriate moisturizer [1]. Hydration of the skin
helps to improve dryness, reduce pruritus, and restore the
disturbed skin’s barrier function. Bathing without use of a
moisturizer may compromise skin hydration [23–25].
Hence, use of emollients is of paramount importance in
both prevention and management of AD [1, 20].
Many proprietary emollients claim to replace ceramide
ingredients, but few have been tested. This pilot study
Table 1 Global acceptability of treatmenta
Acceptability Emollient [n] Body wash [n]
LMF moisturizer Other proprietary product Moisturizing wash Other proprietary product
Very good 3 1 3 0
Good 13 13 10 11
Fair 7 10 11 13
Poor 1 0 0 0
LMF ceramide-precursor lipids and moisturizing factors
a When the data were analyzed for the strength of the agreement of the rating of acceptability, the j values were 0.338 (fair) for use of body wash
and 0.118 (poor) for use of emollients before and after the trial
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explored patient acceptability of a moisturizer containing
lipids and natural moisturizing factors, and evaluated its
efficacy in AD. We showed that the LMF moisturizer was
considered acceptable by two thirds of the patients with
AD. It seems that patients who found the moisturizer
acceptable were less likely to be female or to be colonized
by S. aureus before switching to the LMF moisturizer, and
they had less severe eczema, less pruritus, and less sleep
disturbance following its use than patients who did not find
the product acceptable. Gender and S. aureus colonization
may have influenced the patient acceptability and clinical
efficacy of the LMF moisturizer. In the wider context, AD
is a complex multifactorial atopic disease, and mono-
therapy targeted merely at replacement of ceramides,
pseudoceramides, or filaggrin degradation products at the
epidermis is often suboptimal. In particular, colonization
with S. aureus must be adequately treated before emollient
treatment can be optimized [16].
Despite claims about their efficacy, little evidence has
demonstrated short- or long-term usefulness of many pro-
prietary products. Some ceramides and pseudoceramides
have been studied and added to commercial moisturizers to
mimic natural skin-moisturizing factors, and to influence
both TEWL and expression of antimicrobial peptides in
patients with AD [26]. Chamlin et al. [5] assessed the
efficacy of a ceramide-dominant, physiological lipid-based
emollient, when substituted for currently used moisturizers,
in 24 children who were also receiving standard therapy for
‘stubborn-to-recalcitrant’ AD. All subjects continued their
previous therapy (e.g., topical tacrolimus or corticoste-
roids), only substituting the barrier-repair emollient for
their previous moisturizer. Follow-up SCORAD scores
improved significantly in 22 of 24 patients by 3 weeks,
with further progressive improvement in all patients
between 6 and 20 or 21 weeks. TEWL, which was elevated
over the involved and uninvolved areas at study entry,
decreased in parallel with SCORAD scores and continued
to decline even after the SCORAD scores plateaued.
Stratum corneum integrity and hydration also improved
significantly during therapy. The ultrastructure of the
stratum corneum following treatment with the ceramide-
dominant emollient revealed extracellular lamellar mem-
branes, which were largely absent in baseline stratum
corneum samples. The authors concluded that a ceramide-
dominant barrier-repair emollient represents a safe and
useful adjunct to the treatment of childhood AD.
Table 2 Acceptability and efficacy of treatment with the LMF moisturizera
Parameter Very good/good




















Global acceptability of treatment
Male gender [n (%)] 13 (81)c 2 (25) 0.021
Age [years] 13.2 (5.7) 14.8 (5.8) 0.70
Objective SCORAD score (SD) 31.5 (13.7) 25.7 (14.0) 42.3 (22.2) 40.5 (17.6) 0.039 0.46 0.086 0.035
Pruritus score (SD) 5.6 (1.8) 4.9 (2.0) 6.5 (2.3) 6.6 (2.1) 0.20 0.98 0.35 0.043
Sleep disturbance score (SD) 3.6 (3.1) 3.3 (2.6) 5.8 (3.3) 6.3 (3.2) 0.36 0.63 0.15 0.032
Skin hydration [a.u. (SD)] 30.7 (12.3) 36.0 (10.5) 36.1 (16.0) 39.2 (19.8) 0.021 0.38 0.36 0.74
TEWL [g/m2/h (SD)] 11.5 (3.4) 12.3 (4.4) 11.8 (2.8) 12.0 (2.0) 0.56 0.64 0.76 0.39
Staphylococcus aureus in the antecubital
fossa [n]
6 7 6 6 1.0 1.0 0.19 0.21
Worst-affected eczematous area 8 10 8 8 0.63 NA 0.022 0.066
Topical corticosteroid use [n] 8 6 5 3 0.50 0.50 0.68 1.0
Antihistamine use [n] 5 3 6 4 0.50 0.50 0.082 0.17
a.u. arbitrary units, LMF ceramide-precursor lipids and moisturizing factors, NA not applicable, SCORAD SCORing atopic dermatitis,
SD standard deviation, TEWL transepidermal water loss
a Values are expressed as means (SDs) unless stated otherwise
b p values of B0.05 are statistically significant. The p values presented are for comparisons between pre- and post-treatment in the very good/
good acceptability group [(1) versus (2)], comparisons between pre- and post-treatment in the fair/poor acceptability group [(3) versus (4)],
comparisons between the very good/good and fair/poor acceptability groups pre-treatment [(1) versus (3)], and comparisons between the very
good/good and fair/poor acceptability groups post-treatment [(2) versus (4)]
c The odds ratio for very good/good acceptability of LMF moisturizer in female patients was 0.089 (95 % confidence interval 0.006–0.793)
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EpiCeram consists of a specific combination of cera-
mides, cholesterol, and fatty acids (in the ratio of 3:1:1),
which mimic those naturally found in the skin [27, 28].
Recent studies have shown that EpiCeram has efficacy
similar to that of a mid-potency topical corticosteroid but
has a more favorable safety profile [27, 28]. However,
those studies did not report objective measurements to
demonstrate the efficacy of treatment.
Hon et al. [29] studied skin hydration and TEWL on the
forearm and determined the SCORAD score, Nottingham
Eczema Severity Score (NESS), CDLQI, and amounts of
emollient and cleanser used over a 2-week period in con-
secutive new patients seen at the pediatric skin clinic.
Patients with AD had significantly greater TEWL and less
skin hydration at the studied sites. Although both skin dry-
ness and skin hydration were improved, there was no sig-
nificant improvement in the SCORAD score or TEWL after
2 weeks. In terms of GAT, three quarters of patients with AD
and controls rated the combination of the cream and cleanser
as good or very good. The authors concluded that liberal use
of emollients and bathing cleanser alone does not seem to
alter disease severity or TEWL within 2 weeks, implying
that additional treatments are necessary to manage AD [29].
In another study, Hon et al. [13] recruited 33 patients
with AD to study the clinical and biophysiological effects
of twice-daily application of a pseudoceramide-containing
cream. Four weeks after the patients started using the
pseudoceramide cream, their skin hydration had improved
significantly. There was no deterioration in TEWL, eczema
severity, or quality of life in these patients. The pseudo-
ceramide cream improved skin hydration but not eczema
severity or quality of life over 4 weeks of use [13, 30].
A number of topical preparations are available on the
market. The actual ingredients of most of these products
are a commercial secret of the individual pharmaceutical
companies. However, the active ingredients are identified
on the packaging. The type of moisturizer or emollient
should be tailored to the individual skin condition as well
as the child’s needs and preferences [31, 32].
In terms of GAT, the current study showed that only two
thirds of the AD patients considered the acceptability of the
product to be very good or good, and one third considered
its acceptability to be fair or poor. It seems that patients
who found the LMF moisturizer acceptable were less likely
to be female, to be colonized by S. aureus, and to have
been using an antihistamine before switching to the mois-
turizer, and they had less severe eczema and less sleep
disturbance following its use than patients who did not find
the product acceptable. Gender and S. aureus colonization
may have influenced the patient acceptability and clinical
efficacy of the trial moisturizer. The low acceptability of
these products reflects the fact that there is no user con-
sistency in the preference, acceptability, and choice of
emollients. The major hindrance to the efficacy of a
moisturizer is the patient’s perception as to what an ideal
moisturizer should be like [8]. This perception varies from
person to person. Therefore, the physician caring for a
patient with AD must educate and guide the parents and the
patient to choose the most acceptable formulation to ensure
optimal compliance. Ultimately, an ‘ideal’ emollient is an
individualized choice that the patient will accept and use.
This pilot study provides insights for further research
into ceramide-containing emollients. First, patient accep-
tance of the strengths, types, and formulations of ceramides
and related products needs to be studied in randomized
controlled trials of any novel products. Second, efficacy
studies holistically focusing on all clinical parameters
(namely severity scores, quality-of-life indices, skin
hydration, TEWL, S. aureus colonization, and patient
acceptability) must be performed. Third, as AD is not a
simple epidermal skin disease but, rather, is a complex
atopic disease, use of an emollient alone is bound to be
suboptimal in efficacy. In the current study, it was evident
that S. aureus colonization was prevalent especially in
patients with moderate-to-severe disease, thus future ran-
domized controlled trials should include a run-in period to
eradicate such colonization in order to evaluate the net
effects due to the emollient.
5 Conclusion
The incorporation of ingredients containing ceramides,
pseudoceramides, and natural moisturizing factors into
therapeutic moisturizers targets the pathophysiology of
AD. Well designed, large-scale, randomized, placebo-
controlled trials are needed to document therapeutic effects
on disease severity, dermatological biophysical parameters,
quality of life, and patient acceptability. Patient accept-
ability of a certain product is pivotal to compliance and
clinical outcome.
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